Sienna Seeks Listing on ASX with IPO


Sienna has applied to the ASX for listing on the Australian Stock Exchange.

The company plans to issue up to 30,000,000 fully paid ordinary shares at a price of $0.20 per share, with the goal of raising a minimum of $4 million and a maximum of $6 million. The offer is now open, with subscriptions closing on July 17th, 2017.

Sienna CEO, Matthew Hoskin said “This is an extremely exciting time for Sienna.  Revenues from Sienna’s IVD product that was recently registered with the US Food and Drug Administration, have now commenced. The company is looking to raise capital to deliver on its growth strategies. Specifically, these funds will be used to grow revenue for the IVD product in the bladder cancer application, and expand into new markets with a focus on Europe and Asia. Sienna will also undertake research with a view to extending the application of our existing IVD product into additional cancer applications, and identify and acquire new technologies for Sienna’s product pipeline.”  

Full details of the offer can be found in the prospectus along with the application form, at

In related news, long term board member and Sienna’s largest shareholder, Mr David Neate, has retired from the Sienna board. Sienna chairman Dr Geoff Cumming said “We thank David for the 12 years that he has served on Sienna’s board.  His contributions to the company have been enormous, both as a board member and as an investor in the company.  While David is stepping down from his board position, he has agreed to remain as an advisor to the Sienna board and management team. The board and management are extremely grateful for David’s contribution to Sienna’s growth and look forward to delivering further success to David and our other shareholders.". 

Mr Neate observed "It is a great pleasure to have been a part of the Sienna story and to see the company's progress to this point. I first became involved with Sienna out of a desire to contribute to the fight against cancer. Being part of the successful development and launch of a product that may assist in the diagnosis of cancer is extremely satisfying. The board and management have my unqualified support through the IPO process and beyond, and I'm highly confident that the company is in an excellent position to continue to deliver on its mission to improve diagnostic healthcare while creating real value for shareholders."


No Very

Captcha Image

Sign up for updates